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ABSTRACT 
OBJECTIVE: To identify novel microRNA (miR) associations in synovial fibroblasts 
(SFs), by performing miR expression profiling on cells isolated from the human TNF 
transgenic mouse model (TghuTNF, Tg197) and patients biopsies. 
METHODS: miR expression in SFs from TghuTNF and WT control mice were 
determined by miR deep sequencing (miR-seq) and the arthritic profile was established 
by pairwise comparisons. qPCR analysis was utilised for profile validation, miR and 
gene quantitation in patient SFs. Dysregulated miR target genes and pathways were 
predicted via bioinformatic algorithms and validated using gain-of-function coupled 
with reporter assays experiments. 
RESULTS: miR-seq demonstrated that TghuTNF-SFs exhibit a distinct pathogenic profile 
with 22 significantly upregulated and 30 significantly downregulated miRs. Validation 
assays confirmed the dysregulation of miR-223, miR-146a and miR-155 previously 
associated with human rheumatoid arthritis (RA) pathology, as well as that of miR-
221/222 and miR-323-3p. Notably, the latter were also found significantly upregulated 
in patient RASFs, suggesting for the first time their association with RA pathology. 
Bioinformatic analysis suggested Wnt/Cadherin signaling as a putative pathway target. 
miR-323-3p overexpression was shown to enhance Wnt pathway activation and 
decrease the levels of its predicted target BTRC, an inhibitor of β-catenin. 
CONCLUSIONS: Using miR-seq based profiling in SFs from the TghuTNF mouse 
model and validations in RA patient biopsies, we identify miR-221/222 and miR-323-
3p as novel dysregulated miRs in RASFs. Furthermore, we show that miR-323-3p is a 
positive regulator of WNT/cadherin signaling in RASFs suggesting its potential 
pathogenic involvement and future use as a therapeutic target in RA. 
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INTRODUCTION 
 
The multifactorial and complex molecular pathogenesis of RA creates hurdles in the 
understanding and treatment of this debilitating disease. Animal models of RA have 
been essential in overcoming patient heterogeneity, thus aiding basic understanding of 
biological mechanisms, identification and validation of novel pathogenic pathways 
and evaluation of diagnostic and therapeutic agents.[1] Nevertheless, despite all efforts 
to date, the aetiology and comprehensive therapy of RA still remains elusive, 
warranting further study into its molecular mechanisms. 
miRs, a class of small non-coding RNA molecules, act as posttranscriptional 
regulators and are involved in a plethora of cellular functions. They function 
predominantly by silencing target genes by binding to the 3’ UTR of their mRNA, in a 
sequence-specific manner, inhibiting mRNA translation or inducing mRNA 
degradation.[2] miRs are highly abundant and show high stability in biological fluids, 
with changes in their levels correlating with disease prognosis and/or activity, 
nominating these molecules valuable disease biomarkers.[3] In addition, miRs have 
attracted a great deal of attention as potential therapeutic targets, as the sequence-
specific mode in which they act allows the simultaneous targeting of multiple target 
genes, often members of the same biological pathway(s).[4] In the context of RA, miR-
155, miR-146a, miR-223, miR-16 and miR-132 have been found dysregulated in 
patient peripheral blood mononuclear cells (PBMCs) and various biological fluid 
samples including synovial fluid and plasma, providing a putative diagnostic 
potential.[5,6]  
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A key cell type mediating RA pathogenesis is the SF, with current concepts 
proposing that therapeutics targeting RASFs could act synergistically with existing 
approaches leading to more favourable outcomes.[7] Thus, better understanding of the 
molecular changes occurring in RASFs is paramount for the generation of targeted 
therapeutics. miR perturbations have been reported in  RA patient SFs including the 
overexpression of miR-155, miR-146a and miR-203, and the underexpression of miR-
124a.[8–10]  
In this study, we hypothesised that additional perturbations in RASF miR 
expression are currently masked by the heterogeneity present in patient genetic 
backgrounds and treatment regimes. To overcome this limitation, we used the 
TghuTNF mouse, a well-established mouse model of human RA that due to huTNF 
deregulated expression develops spontaneous arthritis characterized by infiltration of 
inflammatory cells, synovial hyperplasia, cartilage destruction and bone erosion, 
closely resembling human pathology.[11] The development of full pathology in these 
mice is not dependent on haematopoietic TNFRI,[12] but interestingly mediated by the 
direct activation of TNFR1 on SFs.[13] Thus, aiming to identify novel miRs associated 
with the arthritic phenotype of RASFs we performed miR expression profiling on 
TghuTNF-SFs and validated the results on human RASFs. 
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MATERIALS AND METHODS  
Mice 
TghuTNF mice were generated as previously described.[11] All mice were bred and 
maintained on a mixed CBA×C57BL/6J genetic background in the animal facilities of 
the Biomedical Sciences Research Center (BSRC) Alexander Fleming under specific 
pathogen-free conditions. All mice were used in accordance with the guidance of the 
Institutional Animal Care and Use Committee of BSRC Alexander Fleming. 
 
Mouse and human cell isolation and culturing 
Primary mouse SFs were isolated from fully diseased 8-week-old TghuTNF and WT 
littermate mice (two mice per genotype were used for miR-seq experiment and five to 
eight mice per genotype were used for profile validation) and cultured for three 
passages as previously described.[14] Cell purity of all preparations, was accessed via 
FACS. Representative profiles of the two TghuTNF and two WT SF cultures used for the 
miR-seq experiment are shown on Figure S1. Human RA and osteoarthritis (OA) SFs 
were isolated and cultured as previously described.[10] Synovial tissue specimens 
were obtained during synovectomy or joint replacement surgery from patients with RA 
and patients with OA, after informed consent was obtained from all patients. The local 
ethics committee approved the study. All RA patients fulfilled the American College of 
Rheumatology criteria for the classification of RA.[15] All experiments using human 
cells were performed with SFs in passages 4-7. 
 
RNA isolation 
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Total RNA was isolated from cultured mouse and human cells using the miRVana™ 
miR Isolation Kit (Ambion) according to the manufacture’s protocol. 
 
miR-seq and miR expression profile generation 
miR-seq 
miR-seq was performed on RNA from SFs isolated from two TghuTNF and two WT 
littermate mice. Libraries were prepared as follows: the 20-30 and 70-100 nucleotide 
fractions were isolated from 10ug of total RNA after being run in a 15% Urea-TBE gel 
(Invitogen) for 1h. The RNA contained on the excised gel bands was eluted on 300µl of 
0.3M NaCl solution during 4h at RT and constant rotation. The elute was separated 
from the gel debris through a Spin-X-column (Fisher) and RNA was precipitated by 
adding 750µl of 100% ethanol and 3µl of glycogen (Ambion) (1mg/ml) and incubating 
it for 30min at -80°C. The precipitated RNA was centrifuged at 14K rpm for 25 min at 
4°C, washed with 75% ethanol and resuspended on 5.7µl of RNAse free water. A 5’ 
adaptor was ligated to the RNA in a reaction containing the full amount of RNA 
recovered from last step, 1.3µl of SRA 5’ adaptor (Illumina), 1µl T4 RNA ligase (10U/µl) 
(Promega), 1 µl 10X T4 RNA ligase reaction buffer (Promega) and 1 µl RNAseOUT 
(Invitrogen). The reaction was incubated at 20°C in a thermal cycler for 6h. The 
resulting product was run on a 15% Urea-TBE gel (Invitrogen) and the band 
corresponding to 40-60 nucleotides was excised. The 5’ ligated RNA was eluted and 
precipitated as described before and finally resuspended in 6.4 µl of RNAse free water. 
A 3’ adaptor was added to these molecules in a reaction containing the entire 5’ 
ligated RNA recovered from last step, 0.6 µl of SRA 3’ adaptor (Illumina), 1µl T4 RNA 
ligase (10U/µl) (Promega), 1 µl 10X T4 RNA ligase (Promega) and 1 µl RNAseOUT 
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(Invitrogen). The reaction was incubated at 20°C in a thermal cycler for 6h. The 
product obtained was run on a 10% Urea-TBE gel (Invitrogen) and the band 
corresponding to 70-90 nucleotides was excised. The 5’ and 3’ ligated RNA was eluted 
and precipitated as described before and finally resuspended in 4.5 µl of RNAse free 
water. In order to synthesize single stranded DNA from this material, 0.5 µl of SRA RT-
primer (Illumina) were added to it and the mixture was incubated at 65°C for 10 min. 
This was complemented with 2 µl of 5X first strand buffer, 1 µl 100mM DTT, 0.5 µl 
RNAseOUT (all from Superscript II reverse transcription kit (Invitrogen) and 0.5 µl 
12.5mM dNTP mix (BioLine) and incubated at 48°C for 3 min. After adding 1 µl of 
Superscript II retrotranscriptase (Invitrogen), the reaction was incubated at 44°C for 1h. 
A PCR reaction was then set up with the resultant product and 0.5ul GX1 primer, 0.5ul 
GX2 primer (both from Illumina), 0.5ul 25mM dNTP mix (Bioline), 10ul 5X cloned Phu 
buffer, 0.5ul Phu polymerase (both from NEB) and 28ul RNAse free water. The cycling 
conditions were as follows: 1 cycle of 98°C for 30 sec; 15 cycles of 98°C for 10 sec, 
60°C for 30 sec and 72°C for 15 sec; 1 cycle of 72°C for 10 min. The PCR product was 
purified by running it on a 10% TBE-PAGE gel for 35 min. The band around 90bp was 
excised and eluted on 100ul of 1X Elution buffer 2 (NEB) for 2h at RT and at constant 
rotation. The elute was separated from the gel debris through a Spin-X-column (Fisher) 
and DNA was precipitated by adding 1µl of glycogen (1mg/ml) (Ambion), 10ul 3M 
sodium acetate (Ambion) and 325µl of -20°C100% ethanol and centrifuging at 14K 
rpm for 20 min. After a wash with 70% ethanol, the DNA was vacuum dried and 
resuspended in 10ul of water. The libraries were sequenced using an Illumina GA II 
machine according to manufacturer’s standard protocols at 36bp read length. 
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Alignment algorithm   
Our short sequence alignment method is based on a de Bruijn graph representation of 
the reference collection of known miR sequences.[16] This collection contained all 
murine major and minor (or star) mature miRNAs as defined in mirBase release 15.0, 
giving a total of 707 sequences. All 9mers occurring in each reference sequence and its 
reverse complement were stored in a hash table together with an identifier for the 
reference sequence and its start position within the sequence. For each read, all valid 
paths through the reference sequences were collected, allowing for up to 2 sequence 
edits (mismatches, insertions or deletions). 
 
TghuTNF-SF miR expression profile generation 
For miR expression profile generation miR transcript abundance (sequencing reads) 
was used as a measure of expression. To allow pairwise comparisons, as a common 
practice, miR read numbers in each sample were normalised to the total reads per 
million. All miRs that had less than 6 reads in any of the samples were considered as 
not being expressed and discarded. Subsequently, expression fold change (FC) was 
calculated by dividing the average TghuTNF reads by the average WT reads. miRs 
showing a FC of less than 1.5 were also discarded. Significant differences in the 
expression of the remaining 141 miRs between the two groups were determined using 
an unpaired two-sided t-test, on the log2-transformed reads, as proposed by Creighton 
et al.[17] miRs with a p-value of less than 0.05, fold change greater than 1.5 and a 
false discovery rate (FDR) of less than 5% (calculated according to Storey JD and 
Tibshirani R.,2003)[18] were considered significantly dysregulated. All Sequencing 
Data has been deposited on Gene Expression Omnibus (GEO) with ID: GSE31667. 
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Profile validation and human patient SF miR and gene expression quantitation 
Profile validation was performed on TghuTNF (n≥5) and WT (n≥5) SFs isolated in 
independent experiments, using quantitative real-time polymerase chain reaction 
(qPCR) based TaqMan® MiR Assays (Applied Biosystems) according to the 
manufacturer’s instructions, on a Chromo4 Real-Time PCR detection system (Bio-Rad 
Laboratories). Small nuclear RNA U6 (snU6) was used as an endogenous control for 
normalisation purposes and expression FCs were calculated using the ΔΔC(t) 
method.[19] Samples with a C(t)>35 were considered below detection. 
Human patient quantitations of miRs, CSNK1A1, BTRC and GSK3B were performed on 
RASFs and OASFs as a control, using the same qRT-PCR assays described above, on a 
7500 real-time PCR system (Applied Biosystems). let-7a miR was used as an 
endogenous control for miR measurements while ribosomal 18S levels were used for 
mRNA measurements. Differences in expression were assessed using the ΔC(t) method, 
as previously described.[9,10] For the detection of CSNK1A1, BTRC and GSK3B, 
SYBR® dye and the following primers pairs were used: CSNK1A1 forward (fw) 
CGGCGAGGAAGTGGCAGTGA, reverse (rev) TGGGGATGCCTGGCCTTCTGA; BTRC 
fw CCCGTGCTCCTGCAGGGACA, rev CGGAATGCTCCACAAGGGTCCG; GSK3B 
transcript variant 1 fw TCAGGAGTGCGGGTCTTCCGA, rev 
CAGTGCAATTGCCTCCGGTGGA; GSK3B transcript variant 2 fw 
TTGGACTAAGGTCTTCCGACCCCG, rev CAGTGCAATTGCCTCCGGTGGA. 
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Bioinformatics 
miR expression clustering and heatmap generation 
Pearson correlation based clustering and heatmap generation of miR expression 
profiles was calculated using the made4 package for the the R statistics 
environment.[20]  
 
miR target prediction and pathway analysis 
Human and mouse miR target predictions were performed using the DIANA microT 
and TargetScan algorithms.[21,22] The g:Profiler tool was used for all gene ID 
conversion purposes [23] and the Panther repository was used for pathway enrichment 
analysis.[24]  
For each species miR targets, we combined the unions of the two algorithms outputs, 
which weight species conservation of predicted targets differentially, producing more 
sensitive target lists. By comparing the mouse and human gene target lists we 
generated for each miR lists of conserved, mouse specific and human specific targets 
(Supplementary excel). Pathway enrichment analysis was performed on the conserved 
lists, using the species specific lists as controls to exclude random enrichment, against 
the default Homo sapiens reference gene list provided by Panther. Pathways with p-
value<0.001 were considered significantly enriched.  
 
miR overexpression and WNT reporter assays 
Co-transfections of a human cell line with a WNT reporter plasmid and miR precursors 
(pre-miRs) were performed to clarify miR and pathway relationship, whereas, 
transfections of RASFs with pre-miRs were used to assess the regulatory potential of 
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miRs on target genes. HEK 293T cells were used for reporter plasmid transfections (a 
kind gift from Dr Hatzis, Fleming, Athens). Pre-miR™ miRNA Precursors (Ambion) 
were used for miR overexpression. The M50 Super 8x TOPFlash[25] wnt repoter 
plasmid was purchased from Addgene  and a CMV/GFP expressing plasmid was used 
to control transfection efficiency. The Lipofectamine® 2000 (Invitrogen) reagent was 
used for plasmid and pre-miR transfections and the Steady-Glo® Luciferase Assay 
System was used for luciferase activity quantitation. Luminescence and GFP 
fluorescence were measured on an Infinite® M200 multimode reader (Tecan). Assays 
were performed according to the Pre-miR™ miRNA Precursor guidelines. 
Briefly, for each transfection 104 HEK 293T cells were seeded in one well of Corning® 
96 Well Flat Clear Bottom White Polystyrene TC plates and transfected using the lipid-
mediated forward co-transfection method with 50nM pre-miR (25nM of each miR in 
the case of miR-221/222), 40ng Super 8x TOPFlash plasmid and 4ng CMV/GFP for 48 
hours. After 48 hours, the WNT pathway was activated by treating the cells with 10mM 
LiCl for 16 hours, followed by cell lysis and quantitation of luminescence and 
fluorescence. Each miR, including the control, was transfected four times in each 
experiment and each experiment was repeated three times.  
For transfection of RASFs with pre-miRs, cells were seeded at 50 x 104/well in 12 well 
plates and transfected with 50 nM pre-miR™ 323-3p or pre-miR™ negative control 
(Ambion) using Lipofectamine® 2000 (Invitrogen). Medium was changed after 24h, 
and cells were lysed with QIAzol® lysis reagent (Ambion) 72h after transfection. Total 
RNA was isolated using the miRVana™ miR Isolation Kit (Ambion) and expression of 
target genes was measured with the 7500 real-time PCR system as described above. 
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Statistics 
Statistical analyses were performed using GraphPad Prism. For profile validation 
purposes, significant (p<0.05) FCs between the two groups were computed using a 
one-sample t-test. Pearson’s correlation coefficient was used as similarity measure of 
miR-seq and qPCR based FC, after Gaussian distribution was checked using the 
Shapiro-Wilk’s test.  
Significant differences (p<0.05) between RA and OA SFs miR expression were assessed 
using unpaired two-tailed t-tests on qPCR ΔC(t) values, after Gaussian distribution was 
checked using the Kolmogorov-Smirnov test for n=5 or Shapiro-Wilk’s for n≥6. 
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RESULTS 
 
TghuTNF-SFs exhibit a distinct pathogenic miR expression profile overlapping with 
that of RA patient SFs 
 
The miR expression profiles of SFs isolated from two fully diseased 8week old 
TghuTNF and two healthy WT littermate mice were determined by miR-seq. Pairwise 
significance analysis of the two profiles showed that 22 miRs are upregulated and 30 
miRs downregulated in TghuTNF-SFs, FC>1.5, p-value<0.05 and FDR<5% (Figure 1A 
and Table S1). All Sequencing Data has been deposited on GEO with ID: GSE31667. 
Profile validation was performed on a panel of 13 randomly selected miRs via qPCR, 
on independently isolated pairs of SFs (n≥5). The upregulation of miR-223, miR-146a, 
miR-155, miR-221, miR-222 and miR-323-3p, and downregulation of miR-322 and 
miR-335 in TghuTNF-SFs was confirmed, while the dysregulation of miR-138 and miR-
503 was not and miR-122a, miR-203 and miR-378 levels were below the assay 
detection capacity (Figure 1C and Table S1). 
The validity and quantitative capacity of the sequence-based expression profile 
was further underlined by the significant positive correlation (r=0.9782, p<0.0001, 
n=10) of miR-seq and qPCR based FC, determined via Pearson correlation analysis 
(Figure 1D). 
Current literature on the association of miRs with RASFs report miR-155, miR-
146a and miR-203 overexpression, and reduced levels of miR-124a in RASFs 
compared to OASFs.[8–10] Our results show that miR-203 is downregulated in the 
TghuTNF-SF profile, but was below detection in qPCR validation assays (Figure 1A, 1C, 
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Table S1 and S2). In addition, miR-124 transcripts could not be detected in any of the 
four samples sequenced (Data not shown). In contrast, miR-155 and miR-146a are 
indeed over-expressed in TghuTNF-SFs (Figure 1A, 1C and Table S2), indicating that 
the profile overlaps with the current RA patient SF findings. 
 
TghuTNF-SF and RASF miR expression profile comparison identifies miR-221/222 and 
miR-323-3p association with RASFs 
 
Next we examined our hypothesis that additional miR perurbations are shared between 
TghuTNF-SFs and RASFs. To this end, the validated mouse profile miRs were 
quantitated via qPCR in patient RASFs (n=8) using OASFs (n=8) as a control.  
 
No significant differences were found in miR-223, miR-335, miR-424 (homologue of 
mouse miR-322) or notably miR-146a expression, which has previously been reported 
to be altered in RASFs.[10] This incomplete penetrance of miR-146a may be due to 
heterogeneity present in patient samples. Interestingly, miR-155 dysregulation was 
verified and most notably we found that miR-221, miR-222 and miR-323-3p are 
significantly over-expressed in RASFs, establishing for the first time their association 
with RA (Figure 2, Table S3). 
 
In silico predictions of miR-221/222 and miR-323-3p conserved targets and pathways 
Subsequently, we investigated the putative functional role of the newly associated 
miRs. To this end, pathway enrichment analysis was performed using Panther [24] on 
sensitive lists (Materials and Methods, Supplementary excel) of conserved miR gene 
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targets in humans and mice, predicted by two major target prediction algorithms, 
namely DIANA microT and TargetScan.[21,22] Human and mouse specific target lists 
(Supplementary excel) were used as controls, to exclude enrichment due to 
redundancy often observed in these types of analyses.  
miR-221 and miR-222 were studied simultaneously, as they are a co-expressed 
cluster of miRs, possessing identical 5’ seed regions targeting the same genes. The miR-
221/222 conserved target gene list (978 genes) showed a significant enrichment 
(p<0.001) in 11 pathways, whereas 3 pathways were enriched in the mouse specific 
target list (1420 genes) and the human specific list (2040 genes) showed no significant 
enrichment in any pathways (Table 2 and Supplementary excel). The miR-323-3p 
analysis revealed a significant enrichment in 18 pathways in the conserved target list 
(1711 genes), no significant enrichment in mouse specific list (1326 genes) and one in 
the human specific list (3077 genes) (Table 3 and Supplementary excel). All target 
genes involved in enriched pathways are provided (Supplementary excel). 
Interestingly, pathways previously associated with RA pathogenesis, such as 
wnt,[26,27] cadherin,[28] angiogenesis,[29] Ras,[30] PI3K,[31] PDGF,[32] T cell 
activation[33] and integrin[29] pathways were enriched in both miR target lists, 
implying that the newly identified miRs may modulate more than one key arthritogenic 
pathways.  
 
Table 2. Pathway enrichment analysis of miR-221/222 conserved predicted target 
genes. (ONLINE ONLY MATERIAL) 
 
Pathway 
Reference 
Gene 
Numbera 
(Total: 
19911) 
Conserved 
Target Gene 
numberb 
(Total: 978) 
Expected 
numberc 
Enrichment 
p-value 
17 
Wnt signaling pathway 317 46 15.57 2.03E-10 
Cadherin signaling pathway 147 26 7.22 4.34E-08 
Angiogenesis 191 27 9.38 1.76E-06 
Alzheimer disease-presenilin 
pathway 
122 18 5.99 5.22E-05 
Ras Pathway 79 14 3.88 5.30E-05 
PI3 kinase pathway 115 16 5.65 2.54E-04 
Metabotropic glutamate receptor 
group II pathway 
51 10 2.51 2.75E-04 
Muscarinic acetylcholine receptor 
2 and 4 signaling pathway 
62 11 3.05 3.21E-04 
Metabotropic glutamate receptor 
group III pathway 
73 12 3.59 3.46E-04 
PDGF signaling pathway* 159 19 7.81 4.61E-04 
T cell activation 102 14 5.01 6.84E-04 
aNumber of human genes in panther pathway 
bNumber of conserved targets genes in panther pathway 
cExpected number of conserved target genes based on list size 
*Also enriched in mouse specific target gene list (p-value=2.90e-04) (supplementary 
excel file) 
 
Table 3. Pathway enrichment analysis of miR-323-3p conserved predicted target 
genes. (ONLINE ONLY MATERIAL) 
Pathway 
Reference Gene 
Numbera 
(Total: 19911) 
Conserved 
Target Gene 
numberb 
(Total: 1711) 
Expected 
numberc 
Enrichment 
p-value 
Wnt signaling pathway 317 69 27.24 8.98E-12 
Cadherin signaling 
pathway 
147 35 12.63 1.49E-07 
Angiogenesis 191 37 16.41 7.61E-06 
Inflammation mediated 
by chemokine and 
cytokine signaling 
pathway 
283 46 24.32 4.99E-05 
Metabotropic 
glutamate receptor 
group II pathway 
51 15 4.38 5.35E-05 
Endothelin signaling 
pathway 
91 21 7.82 6.56E-05 
EGF receptor signaling 
pathway 
135 27 11.6 7.28E-05 
Metabotropic 
glutamate receptor 
group III pathway 
73 18 6.27 9.47E-05 
Axon guidance 
mediated by 
semaphorins 
43 13 3.7 1.26E-04 
Integrin signalling 
pathway 
181 32 15.55 1.58E-04 
PDGF signaling 
pathway 
159 29 13.66 1.89E-04 
Ras Pathway 79 18 6.79 2.44E-04 
18 
 
T cell activation 102 21 8.77 3.01E-04 
Heterotrimeric G-
protein signaling 
pathway-Gq alpha and 
Go alpha mediated 
pathway 
134 25 11.51 3.65E-04 
Ubiquitin proteasome 
pathway 
70 16 6.02 5.09E-04 
Parkinson disease 100 20 8.59 5.88E-04 
Apoptosis signaling 
pathway 
123 23 10.57 5.95E-04 
GABA-
B_receptor_II_signaling 
40 11 3.44 8.70E-04 
aNumber of human genes in panther pathway 
bNumber of conserved targets genes in panther pathway 
cExpected number of conserved target genes based on list size 
 
miR-323-3p enhances Wnt/cadherin pathway activation 
 Pathway enrichment analysis indicated Wnt and Cadherin signaling as the top 
pathways potentially affected by both miR-221/222 and miR-323-3p overexpression. 
Activation of wnt/cadherin signaling in RA has been reported and the constitutive 
upregulation of β-catenin, a common component of both pathways,[34] has been 
linked to the RASFs activated phenotype.[26–28,35,36] Accordingly, gain of function 
experiments showed that WNT reporter activity induced by lithium salt treatment,[37] 
was significantly increased in HEK 293T cells overexpressing miR-323-3p (Figure 3A). 
miR-221/222 overexpression showed no effect. 
 Interestingly, CSNK1A1 (casein kinase I isoform alpha), BTRC (beta-transducin 
repeat containing) and GSK3B (glycogen synthase kinase 3 beta) that are known 
mediators of the degradation of β-catenin,[38] were predicted targets of miR-323-3p 
(Supplementary excel). Subsequent qPCR determination of their expression levels 
showed that while CSNK1A1 expression was not significantly changed, both GSK3B 
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transcript variants, GSK3Btr1 and GSK3Btr2, and BTRC expression was found 
significantly decreased in RA compared to OA SFs (Figure 3B).  
 To determine if BTRC and/or GSK3B are regulated by miR-323-3p, we 
overexpressed miR-323-3p in RASFs, which led to the significant decrease of BTRC 
mRNA, whereas neither of the GSK3B transcripts was affected (Figure 3C). In addition, 
miR-323-3p and BTRC expression levels showed a significant inverse correlation in 
RASFs (r=-0.5336, p=0.037) (Figure 3D). Collectively these results suggest that miR-
323-3p overexpression leads to enhanced activation of Wnt/cadherin pathways, in part 
by targeting BTRC in RASFs. 
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DISCUSSION 
miRs have been proposed as potentially valuable targets in RA with current literature 
reporting the dysregulated expression of miR-223, miR-155, miR-146a and miR-16 in 
patient PBMCs and synovial fluid, reduced miR-132 levels in RA plasma and miR-155, 
miR-146a, miR-203 and miR-124a dysregulations in patient SFs.[5,6,8–10] miR 
functional studies suggest a protective role for miR-155 in RASFs, as it has been shown 
to reduce matrix metalloproteinase (MMP)-1 and -3 expression.[10] Conversely, in vivo 
functional experiments using miR-155 deficient mice have indicated a pathogenic role 
for miR-155 in immune cells, since deficient mice are protected against antigen driven 
arthritis, through the blockade of antigen-specific T-helper 17 (Th17) polarization and 
show reduced immune-mediated bone destruction in the serum-transfer model of 
arthritis by the partial inhibition of osteoclastogenesis.[39,40] Furthermore, despite 
miR-146a upregulation in various RA patient cell types suggesting a pathogenic role, in 
vivo exogenous double stranded miR-146a administration after the induction of auto-
antigen driven arthritis in mice, led to a decrease in bone erosion via the partial 
inhibition of osteoclastogenesis, with no effect on joint inflammation.[41]  
Whereas studies on human patient samples are paramount in the direct 
identification of disease determinants and therapeutic targets, their heterogeneity 
owing to diverse genetic backgrounds, environmental conditions and treatment 
regimes impedes this discovery process. Animal models of disease, such as the 
TghuTNF model, although not fully representing the heterogeneity seen in RA, they do 
show pathogenic and therapeutic alignment with aspects of human disease, providing 
invaluable tools to overcome such hurdles due to their homogeneity and complete 
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disease penetrance. Thus, comparative studies utilising both sample types should be 
advantageous in the identification of novel pathogenic mechanisms or biomarkers.[1]  
In this study, we overcame limitations possessed by patient heterogeneity by 
using the TghuTNF mouse. We focused on SFs, which are key cells driving human RA 
pathology and can alone instigate full pathology in this mouse model.[12,13] By 
comparing the mouse and human arthritic profiles we found that they overlap and 
importantly we established a miR-221/222 and miR-323-3p association with RASFs. 
The TghuTNF-SF miR expression profile is provided here as a resource, which may 
contain further currently unidentified miR dysregulations associated with human 
pathology. 
A search of current literature did not identify any evidence to support a function 
for miR-323-3p, in contrast miR-221/222 is an established “oncomiR” cluster over-
expressed in various human cancers. The cluster mediates oncogenic transformation in 
cancer cells by enhancing cellular proliferation, inhibiting apoptosis and enhancing 
cellular migration.[42] These functions are also altered in RASFs,[43,44] suggesting 
that they may be regulated by miR-221/222 overexpression.  
Furthermore, utilising in silico target predictions and pathway enrichment analysis, we 
investigated putative target genes and pathways modified by the newly associated 
miRs. Interestingly, the most significantly enriched pathways were Wnt and Cadherin 
signaling. The importance of the Cadherin signaling in RA has been established, as 
Cadherin-11 is necessary for the mounting of an inflammatory response by RASFs and 
maintenance of the correct architecture of the synovium.[28,36] In addition, the role of 
the Wnt pathway has also been initially highlighted by a study by Diarra et al, as the 
inhibition of its key regulator Dickkopf-1 (DKK-1) results in the reversal of the bone-
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destructive phenotype of TghuTNF mice and DKK-1 was shown to be highly expressed 
in RASFs.[26] Moreover, a recent study has further underscored this association of the 
WNT pathway in RASFs, by showing that the pathway activation is epigenetically 
controlled by the enhancer of zeste homologue 2 (EZH2).[27] These key pathways 
contributing to the pathogenic phenotype of RASFs converge at β-catenin.[34]  
Notably, we show here that miR-323-3p enhances Wnt activation. In addition, 
miR-323-3p overexpression, led to the decreased levels of the negative regulator of β-
catenin, BTRC, implying that cadherin signaling may also be modulated. We propose 
that BTRC is only one of the perturbed Wnt/cadherin signaling components and that 
additional key molecules are also regulated by miR-323-3p and/or other miRs 
dysregulated in RASFs. Jointly, these results propose the dysregulation of the 
Wnt/Cadherin pathway as a potential pathogenic target of miR-323-3p in RASFs and 
that intervention using miR-323-3p inhibitors may be of therapeutic value. 
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Figures Legends 
 
Figure 1. The TghuTNF-SF miR sequence-based expression profile.  
Sequence-based expression profile of significantly dysregulated miRs in TghuTNF-SFs 
(n=2) compared to WT SFs (n=2). (A), Top 15 upregulated and downregulated miRs. 
Fold change (Tg / WT) plotted on the y-axis and miR abundance in WT SFs is plotted 
on the x-axis, providing both a measure of dysregulation and expression and (B), 
Pearson correlation coefficient-based clustering heat map representation of the 
expression profile, showing that TghuTNF-SFs express a distinct pathogenic profile 
compared to WT SFs. (C) Average fold change in miR expression in TghuTNF versus 
WT littermate SFs (Data from 5-8 independent experiments combined). Levels were 
determined using TaqMan miR assays. Fold change was calculated using the ΔΔCt 
method. All miR levels were normalised to U6 snRNA. Error bars represent ±SEM. p-
values calculated using a one-sample t-test. bd: Below detection (C(t)>35). (D), Pearson 
correlation between miR fold change determined by sequencing and qRT-PCR, 
showing that the sequence-based expression profile is valid and quantitative (r = 
0.9782, p<0.0001, n=10).  
 
Figure 2. miRs dysregulated in RA versus OA patient SFs. 
Expression differences of miRs in RA (n=8) and OA (n=8) SFs. Levels were determined 
using TaqMan miR assays. Relative expression differences were calculated using the 
ΔC(t) method. All miR levels were normalised to let-7a miR. Bars represent the mean. 
p-values were calculated using an unpaired t-test, ns: not significant. 
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Figure 3. miR-323-3p overexpression, but to not miR-221/222, enhances WNT 
pathway activation and decreases the levels of it’s predicted target BTRC. 
(A), WNT reporter activity in HEK 293T cells transfected for 48 hours with 50nM pre-
miR-323-3p or 50nM pre-miR-221/222 (25nM of each miR-221 and miR-222) or 50nM 
pre-miR-scr (control). WNT activation was induced by treatment with 10mM LiCl for 
16h. Luciferase activity was normalised for transfection efficiency by GFP expression 
and is presented as relative fluorescence units (RFU). Results show that miR-323-3p, 
but not miR-221/222, enhances Wnt activation. Error bars represent ±SEM and n=12 
transfection for each pre-miR.   
(B), Expression differences of CSNK1A1, BTRC and GSK3B, negative regulators of β-­‐‑
catenin, in RA (n=14) and OA (n=10) SFs. Levels were determined by qRT-PCR. 
Relative expression differences were calculated using the ΔC(t) method. All transcript 
levels were normalised to 18s. (C), Expression differences of BTRC and GSK3B in 
RASFs (n=7) transfected with 50nM pre-miR-323-3p or 50nM pre-miR-scr (control), 
showing that miR-323-3p overexpression decreases the levels of BTRC. Levels were 
determined by qRT-PCR. Relative expression differences were calculated using the 
ΔΔC(t) method. All transcript levels were normalised to 18s. Bars represent the mean. 
(D), Pearson correlation between miR-323-3p and BTRC expression in RASFs (n=12), 
showing an significant inverse correlation (r = -0.5336, p=0.037). p-values were 
calculated using an unpaired t-test, ns: not significant.  
 
Figure S1.  Purity of synovial fibroblasts used for miR-seq determined by FACS analysis. 
Representative overlaid histograms showing the percentage of cells and intensity of 
expression of CD90.2 and CD-11b, in SFs isolated from 2xWT and 2xTghuTNF mice 
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cultured for three passages. Black lines represent the unstained control samples. Blue 
lines represent WTSFs and red line TghuTNF SFs. (A) All cell preps were >85% positive 
for CD90.2, showing similar expression intensity. (B) All cell preps were <1% positive 
for the myeloid cell marker CD11b, showing negligible intensity of expression.  
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Supplementary Material 
 
Table S1. Sequence-based miR expression profile of TghuTNF SFs. 
 
microRNA 
Fold Change  
(Tg / WT) p-value 
 
q-value WT abundance 
miR-329 9.1 0.0493 0.002164882 16 
miR-223 6.3 0.0462 0.002164882 9 
miR-146a 6.1 0.0193 0.002154901 32462 
miR-495 5.5 0.0232 0.002154901 15 
miR-221 4.0 0.0385 0.002492094 3822 
miR-122 3.9 0.0138 0.002154901 55 
miR-215 3.8 0.0014 0.002154901 114 
miR-222 3.5 0.0009 0.001131415 4990 
miR-592 2.9 0.0148 0.001131415 14 
miR-31 2.6 0.0374 0.002154901 1228 
miR-155 2.6 0.0239 0.002154901 3149 
miR-129-3p 2.3 0.0017 0.002154901 112 
miR-694 2.2 0.0298 0.006199645 29 
miR-138 2.2 0.0425 0.003285265 122 
miR-22 2.0 0.0392 0.002875388 93439 
miR-667 1.8 0.0188 0.002164882 112 
miR-344 1.8 0.0399 0.004472551 80 
34 
miR-140* 1.7 0.0486 0.001131415 265858 
miR-770-3p 1.6 0.0490 0.002154901 103 
miR-382 1.6 0.0367 0.003371155 6208 
miR-323-3p 1.5 0.0428 0.002164882 42 
miR-433 1.5 0.0182 0.00350631 517 
miR-669b -1.5 0.0350 0.002408699 980 
miR-297a -1.5 0.0185 0.002154901 1226 
miR-669f -1.6 0.0213 0.002787427 77 
miR-466f -1.6 0.0314 0.00350631 955 
miR-467f -1.6 0.0378 0.005546369 918 
miR-466d-5p -1.7 0.0068 0.002154901 73 
miR-126-5p -1.7 0.0244 0.002605797 298 
miR-126-3p -1.7 0.0399 0.004237086 2208 
miR-467d -1.8 0.0166 0.002408699 1226 
miR-676 -2.1 0.0097 0.002154901 9341 
miR-466k -2.1 0.0164 0.007619994 38 
miR-466g -2.1 0.0375 0.003319105 113 
miR-676* -2.1 0.0097 0.002408699 1910 
miR-455* -2.3 0.0405 0.002164882 360 
miR-378 -2.6 0.0225 0.004985264 66737 
miR-708 -2.7 0.0130 0.002164882 313 
miR-203 -2.7 0.0271 0.003319105 1334 
miR-378* -2.7 0.0025 0.004579373 47 
35 
miR-542-3p -2.9 0.0375 0.004413499 708 
miR-450a-5p -3.0 0.0459 0.002164882 128 
miR-708* -3.0 0.0488 0.002767633 49 
miR-322 -3.5 0.0377 0.009036641 1862 
miR-146b* -4.1 0.0252 0.002711552 120 
miR-503* -4.1 0.0267 0.003777431 211 
miR-542-5p -4.3 0.0022 0.002154901 64 
miR-503 -4.9 0.0354 0.002164882 152 
miR-483 -6.2 0.0333 0.006199645 158 
miR-204 -8.1 0.0270 0.003782695 149 
miR-335-3p -14.2 0.0144 0.006619368 460 
miR-335-5p -19.7 0.0495 0.003146091 490 
Significantly dysregulated (Fold Change ≥ 1.5, p-value < 0.05, FDR<5%) miRs in 
TghuTNF SFs (n=2) compared to WT SFs (n=2). miR normalised copy number also 
provided as a measure of expression. 
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Table S2. qRT-PCR measurements of TghuTNF miRNA expression.  
miRNA 
No. of 
experiments 
Fold Change  
(Tg / WT) Standard Error   P-value 
miR-146a 6 7.15 1.54 0.0105 
miR-223 5 6.59 1.40 0.0163 
miR-221 6 4.39 0.77 0.0069 
miR-222 6 3.95 1.04 0.0363 
miR-155 7 2.48 0.54 0.0337 
miR-323-3p 8 1.65 0.21 0.0186 
miR-322 5 0.60 (-1.67) 0.13 0.0387 
miR-335 5 0.10 (-10.00) 0.04 P<0.0001 
miR-138 6 1.03 0.22 0.8828 
miR-503 6 0.72 (-1.39) 0.24 0.2923 
miR-122a 5 bd na na 
miR-203 5 bd na na 
miR-378 5 bd na na 
Average fold change in miR expression in TghuTNF versus WT littermate SFs. 
Expression levels were measured using qRT-PCR. Fold changes were calculated using 
the ΔΔC(t) method. All miR levels were normalised to U6 snRNA. p-values were 
calculated using a one sample t-test. bd: Below detection: C(t) > 35, na: not applicable.  
 
Table S3. qRT-PCR measurements of miRNA expression in RASFs and OASFs. 
miR RASF OASF p-value* 
miR-221 2.12±0.6 1±0.21 0.049 
miR-222 1.72±0.26 1±0.18 0.0192 
miR-323-3p 1.78±0.29 1±0.2 0.0444 
miR-155 1.29±0.1 1±0.09 0.045 
miR-146a 0.4±0.1 1±0.37 0.3069 
miR-223 2.23±0.85 1±0.21 0.2288 
miR-424 1.62±0.35 1±0.32 0.1655 
miR-335 1.07±0.25 1±0.2 0.8507 
Average miR expression ± standard error in RASFs and OASFs. Expression levels were 
measured using qRT-PCR. Expression was calculated using the ΔΔCt method. All miR 
levels were normalised to let-7a. *p-values were calculated using a two-sided t-test 
comparing RASF ΔC(t) and OASF ΔC(t). 
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Table S4. Characteristics of the study patients 
 RA patients 
(n=8) 
OA patients 
(n=8) 
Age, mean (range), years 66.3 (51 - 80) 67.8 (52 - 87) 
Sex, no. female/male 7/1 2/6 
Disease duration, mean (range), years 23.9 (5 - 50) NA 
Medications, no. taking   
NSAIDs 2 3 
MTX 4 0 
leflunomid 2 0 
steroids 3 0 
tocilizumab 2 0 
No. RF+ (>20 IU)/no.assessed 6/7 NA 
DAS28, mean (range) 2.1 (1.38 – 2.8) NA 
NA = not assessed; NSAIDs = nonsteroidal antiinflammatory drugs; RF = rheumatoid 
factor; DAS = disease activity score 
 
Patient information provided to indicate that clinical parameters do not seem to 
influence miR expression levels. 
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